RFK Jr.'s Vaccine Selloff Is Fast-But the Real Repricing Hasn't Hit Yet

The initial vaccine selloff was broad; the harder reset may come later

This selloff began as headline risk.

Since Politico reported the potential selection on Thursday afternoon, Pfizer and GSK have fallen about 5%, Sanofi roughly 4%, and Merck about 3.5%. The bigger hit landed on the more vaccine-sensitive names: Moderna dropped 11% since the Thursday report, and Bavarian Nordic fell 17% on Friday alone.

That was the easy reset.

The harder repricing may come next because this is not just about one controversial appointment. RFK Jr. would oversee both the FDA and the CDC, giving him influence over immunization schedules, recommendations, and federal vaccine policy. That is the mechanism investors still need to track: policy friction can reshape demand signals, investor confidence, and the timing of vaccine-related cash flows.

Bears will argue the market overreacted. They have one credible support: Kennedy has swallowed his trademark vaccine skepticism in recent weeks and avoided making vaccines his main public issue. That keeps the setup from becoming a caricature, but it does not erase the underlying policy risk.

The backdrop is also more fragile than the headline-driven reaction suggests. In 2025, Merck's HPV sales reached $2.6 billion; Sanofi's flu vaccine sales were $1.7 billion; Pfizer's Covid sales were $1.6 billion; GSK's shingles sales were $1.2 billion; and Moderna's RSV and Covid franchise demand totaled $289 million. Those are not fringe assets. They are core cash engines.

So the signal has shifted from announcement risk to policy risk. Once HHS starts shaping FDA/CDC behavior and public messaging around immunization, investors may stop trading the headline and start trading the implications for recommendations, adoption, and investment.

Why the policy threat matters even if the headlines cool off

Process matters more than publicity

The first leg of the trade was sentiment. The second leg is process.

Once the news cycle moves on, investors need to watch whether HHS turns scrutiny into delays, budget fights, and fractured public messaging. That is the real transmission path to earnings: not just rhetoric, but the friction added to the vaccine ecosystem.

Kennedy has already pushed serious policy changes

Kennedy did not just show up with hot takes. He pushed for a proposal to spend billions on a autism-vaccine link study and floated eliminating the entire federal immunization schedule for American children. Even if the most extreme proposals never become law, the threat alone can alter behavior across the vaccine chain.

Courts can slow change, but they do not remove uncertainty

Bears have one real point: Kennedy promised to work within existing vaccine approval and safety systems. That matters. It suggests this is unlikely to play out as a clean, immediate overturning of the status quo.

But that is also why the repricing can be slow and then sudden. When policy is contested, the first impact is often delay. Courts step in. Rules get challenged. Agencies get risk-averse. A federal judge has now paused major changes to the U.S.'s vaccine policies led by HHS, which shows that reform does not automatically mean smooth execution.

For investors, regulatory uncertainty is the key issue. If every major policy move gets litigated, companies can still be hit by postponed demand signals, stretched development timelines, and uneven federal support.

Trust has become part of the demand equation

The operating damage may start small, but the sentiment damage can compound quickly. CNN reported 20,000 employee cuts as part of Kennedy's broader reshaping of HHS, and KFF found that trust in federal health agencies has fallen sharply during his tenure. In vaccine markets, where adoption depends heavily on physician confidence, public confidence, and consistent guidance, that matters.

We already see early signs of that pressure outside Washington: Moderna is pulling back on vaccine studies, one planned vaccine-technology factory canceled construction plans, and another manufacturer laid off workers. Investors have also grown more hesitant to back a sector that has fallen out of favor in Washington.

That is the second-order hit the market may still be underestimating: less invention, less investment, and weaker downstream demand because the policy signal has shifted from support for immunization toward broader skepticism about the framework.

How the market may split vaccine winners and losers

The first selloff hit every vaccine-exposed name after Politico reported the potential selection. The next leg should be more selective.

Higher-beta downside: future-tied vaccine names

Moderna is the clearest watch. Beyond the initial drop, the bigger tell is operational: Moderna is pulling back on vaccine studies. Its current vaccine revenue base is not large enough to absorb policy friction quietly. That makes it more exposed to weaker federal endorsement, slower adoption messaging, and a less willing capital market.

Bavarian Nordic belongs in the same bucket. The market already showed how quickly sentiment can reverse when a name is tied to emerging vaccine capacity and Washington turns hostile, with the stock down 17% on Friday alone. The mechanism is not necessarily a ban. It is slower timelines, weaker demand signals, and a lower multiple on revenue that still needs proving.

More resilience, but not safety: established franchise businesses

The more mature vaccine businesses are not risk-free, but their downside looks more like perception and process pressure than immediate cash-flow damage. Merck, for example, recently agreed to pay $50 million to settle litigation over Gardasil, and senators asked whether Kennedy had a conflict because he was an attorney of record in some of the cases. He oversees agencies that regulate and pay for vaccines, and the letter did not secure a firm recusal.

What would confirm or invalidate the bearish view

Bull-case signs: - major changes to the U.S.'s vaccine policies remain blocked by courts - Kennedy continues to avoid reviving his earlier vaccine rhetoric - No further study pullbacks, manufacturing cancellations, or layoffs show up in the data - Federal immunization messaging remains stable

Bear-case signs: - New moves tied to the federal immunization schedule - More vaccine study pullbacks, manufacturing cancellations, or layoffs - Signs that weaker federal endorsement is slowing adoption